Magazine Article | May 2, 2022

Is Biopharma Poised For Bigger Deals In 2022?

Source: Life Science Leader

By Benet O'Reilly

After total deal value in the biopharma industry dipped to $108 billion in 2021 — its second-lowest level in eight years — it's natural to speculate whether that trend will continue in 2022. Will we see a resumption of transformative dealmaking? Or will we continue to see a high level of lower-value deals featuring bolt-on transactions, partnerships, and alliances?

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader